Form 4: Cue Biopharma Executive Anish Suri Granted Stock Options

Anish Suri, President and CSO of Cue Biopharma, was granted stock options to purchase 150,000 shares of common stock.

Summary

• Anish Suri, the President and CSO of Cue Biopharma, Inc., was granted stock options on June 5, 2024.
• The options allow Suri to purchase 150,000 shares of Cue Biopharma's common stock at an exercise price of $1.65 per share.
• The stock options vest in eight equal semi-annual installments, starting on December 5, 2024.
• The options expire on June 4, 2034.

Sentiment

Score: 7

Explanation: The granting of stock options is generally a positive sign, indicating confidence in the company's future performance and aligning executive interests with shareholders. However, it also represents potential future dilution.

Positives

• The granting of stock options to a key executive like the President and CSO can be seen as an incentive to align their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cue Biopharma.
• Companies such as Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates